Publications by authors named "P A Fasching"

Claim this Profile
D
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala, Eleonora Pagan, Peter A Fasching

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center.
Niklas Amann, Manuel Hörner, Henrik Spannring, Lena Brückner, Julia Gocke, Peter A Fasching

J Cancer Res Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the potential of ChatGPT for patient identification in clinical breast cancer trials.
Annika Krückel, Peter A Fasching, Oliver Schleicher, Julia Gocke, Lena Brückner

Digit Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).
T Link, M Reinisch, M Just, M Untch, N Filmann, P A Fasching

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis